Analytics

Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.

Articles

The European Fine Chemicals Group (EFCG) gave an update of some of its activities at a press conference held at CPhI Worldwide (Spain) last week, and revealed some disturbing facts regarding counterfeit APIs, which the group is particularly concerned about.

EFCG: Counterfeit Medicines More Profitable than Heroin

Company and People Notes: Sanofi Pasteur signs H1N1 vaccine deal with Brazilian government; Helsinn Group appoints CEO of US business; more...

Week of Sept. 14, 2009: Evotec and Biogen Idec Form Pact; Marijn Dekkers Leaves Thermo Fisher Scientific for Bayer; More...

Company and People Notes: UCB and Novartis form agreement; AAIPharma appoints VP of regulatory affairs; more...

Week of Aug. 24, 2009: Warner Chilcott Buys P&G Pharma Business; Amylin Appoints Former Novartis Exec As Chairman; More...

Also: DSM's North Carolina facility receives SafeBridge certification; Dynavax CFO to retire; more...

Company and People Notes: Nabi and GSK Form Pact; Cardinal Health Names CEO; More...

Also, Pfizer forms two research agreements in China; NanoInk appoints John Kubricky to its scientific advisory board; more...

Company and People Notes: Cherokee and DuPont Form Supply Agreement; Mylan Makes Changes in Management Team; More...

Biotech firms must first close the gaps between science and biology on the path toward QbD.

For Biotherapeutics, Innovation is Not Enough

The US Food and Drug Administration last week posted the final version of its Guidance for Industry, ANDAs: Impurities in Drug Substances.

Final Guidance on Listing Drug-Substance Impurities in ANDAs

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Consumer-care products, electronics, and select industrial firms comprise AMR Research's Supply Chain Top 25 for 2009, offering an opportunity for the pharmaceutical industry to examine best practices in supply-chain management.

Best Practices in the Supply Chain

Today, approximately 1.5 million counterfeit medicine packs enter the legal supply chain each year - in other words, one pack in every 20000 is counterfeit.

Why we need mass serialization — now!

Also: Sanofi-aventis acquires BiPar Sciences; FDA issues Warning Letter to Chinese heparin manufacturer; Halo Pharmaceutical appoints chief scientific officer; more...

Drug Substance Analysis